Generic Zyprexa Relprevv
A patent for Zyprexa Relprevv (olanzapine extended-release injection) currently prevents any company from making a generic version of the drug. However, this may change after the patent expires in September 2018. Although olanzapine is often referred to as the "generic name" for Zyprexa Relprevv, it is simply the active ingredient in the drug and not a generic version of it.
Zyprexa® Relprevv™ (olanzapine extended-release injection) is a prescription medication used to treat people with schizophrenia. It is a long-acting injection given every two to four weeks.
Zyprexa Relprevv is manufactured by Eli Lilly and Company. It is currently protected by a patent that prevents any generic Zyprexa Relprevv from being manufactured in the United States.
The patent for Zyprexa Relprevv is set to expire in September 2018. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Zyprexa Relprevv uses. Once the patent expires, there may be several companies that manufacture a generic Zyprexa Relprevv drug.
No -- olanzapine is the active ingredient in Zyprexa Relprevv, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer would make the product.
It should be noted that olanzapine is also the active ingredient in several other products marketed under the brand name Zyprexa®. These other products, which include a short-acting injection, a regular tablet, and an orally disintegrating tablet (a tablet that dissolves in the mouth, marketed under the name Zyprexa Zydis®), are available in generic form (see Generic Zyprexa).